Latest Options News

Imugene Limited has reported compelling clinical trial results for its off-the-shelf CAR T therapy, azer-cel, alongside FDA validation and a strategic collaboration, while managing cash flow amid cost reductions.

Red Mountain Mining has made significant strides in its critical minerals and gold projects across the US and Australia, highlighted by new claim acquisitions and promising exploration results at key antimony prospects.

Culpeo Minerals reports promising high-grade copper intersections at its La Florida Prospect and secures A$3 million to fund upcoming drilling at Vista Montana, advancing its Chilean copper exploration ambitions.

Livium Ltd has solidified its position in the clean energy recycling sector with new contracts, a key patent, and a $4.5 million capital raise, setting the stage for accelerated growth in lithium-ion battery and rare earth element recycling.

BOA Resources has secured a significant foothold in Western Australia’s Murchison Copper Belt with a 49% stake in the Neds Creek copper project, setting the stage for targeted drilling and exploration backed by a $3.75 million capital raise.

Reach Resources has completed a significant drilling program at its Murchison South Gold Project and secured two new mining leases, setting the stage for enhanced resource confidence and potential open-pit development.

Pilot Energy has made significant strides in Q4 2025 with the launch of a modular data centre joint venture, progress on a hybrid solar and battery project, and advancement of offshore gas exploration partnerships, supported by substantial new financing.

Manuka Resources has released an updated 10-year Pre-Feasibility Study for its Cobar Basin projects, revealing a substantial uplift in project economics and a clear path to production by mid-2026.

Power Minerals has commenced a significant 10,000m reverse circulation drilling program at its Santa Anna Project in Brazil, aiming to expand and deepen the footprint of high-grade niobium and rare earth elements mineralisation. Results are anticipated by late March 2026.

Paradigm Biopharmaceuticals reports solid progress in its Phase 3 knee osteoarthritis trial, expanding internationally and publishing key Phase 2 biomarker data. The company maintains a robust cash position to support ongoing clinical milestones.

Noxopharm has successfully completed dosing in its HERACLES clinical trial for SOF-SKN™, demonstrating strong safety and tolerability. The company also secured a new overseas partnership and its first US patent for the Sofra platform.

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.